<DOC>
	<DOC>NCT01521897</DOC>
	<brief_summary>This surveillance aims to figure out 1) use-results, 2) occurrence of adverse events, and 3) factors affecting safety in terms of the safety in infants starting to receive Prevenar at the age of more than 2 and less than 7 months in routine medical practice. This surveillance will specifically focus on the occurrence of the following: 1. Local reactions at the injection site 2. Systemic reactions for each concomitant vaccine (especially fever more than 39CÂ°)</brief_summary>
	<brief_title>Prevenar Special Use-result Surveillance in Japan (Regulatory PostMarketing Commitment Plan)</brief_title>
	<detailed_description>This surveillance will be conducted using a continuous surveillance system, in which each physician enrolls patients who meet the enrollment criteria continuously until the contract sample size is reached.</detailed_description>
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>Infants at the age of more than 2 and less than 7 months Infants who have been vaccinated with Prevenar for the first time Infants expected to complete four vaccinations with Prevenar Vaccination with Prevenar must not be given to any of the following; History of evident anaphylactic reaction to any component of Prevenar or diphtheria toxoid Evident pyrexia Evident serious acute disease Any other infants or children ineligible for vaccination</criteria>
	<gender>All</gender>
	<minimum_age>2 Months</minimum_age>
	<maximum_age>2 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Pneumococcal Vaccine</keyword>
	<keyword>Prevenar</keyword>
	<keyword>7-valent</keyword>
	<keyword>Special Use-result surveillance</keyword>
</DOC>